Company Overview of Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus ba...
500 Arsenal Street
Watertown, MA 02472
Founded in 1995
Key Executives for Enanta Pharmaceuticals, Inc.
Chief Executive Officer
Total Annual Compensation: $683.9K
Chief Financial Officer
Total Annual Compensation: $420.2K
Chief Scientific Officer and Senior Vice President of Research & Development
Total Annual Compensation: $486.4K
Compensation as of Fiscal Year 2013.
Enanta Pharmaceuticals, Inc. Key Developments
Enanta Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014
Aug 11 14
Enanta Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, revenue was $42.051 million against $1.649 million a year ago. Income from operations was $34.895 million against loss from operation of $4.178 million a year ago. Net income before income taxes was $34.931 million against net loss before income taxes of $4.138 million a year ago. Net income attributable to common stockholders was $50.053 million or $2.61 per diluted share against net loss attributable to common stockholders of $4.138 million or $0.23 per diluted share a year ago.
For the nine months, revenue was $45.104 million against $30.704 million a year ago. Income from operations was $24.311 million against $13.730 million a year ago. Net income before income taxes was $24.358 million against $14.070 million a year ago. Net income attributable to common stockholders was $39.480 million or $2.06 per diluted share against net loss attributable to common stockholders of $2.126 million or $0.30 per diluted share a year ago.
Enanta Pharmaceuticals' HCV NS5A Inhibitor EDP-239 Advances into Combination Studies with Alisporivir (DEB025)
Aug 7 14
Enanta Pharmaceuticals, Inc. announced that Novartis has advanced EDP-239, Enanta's NS5A inhibitor for hepatitis C virus (HCV), into drug combination studies with alisporivir (DEB025), a cyclophilin inhibitor being developed by Novartis. These combination studies are part of Enanta's existing collaboration with Novartis for the development of new combination therapies for the treatment of HCV using Enanta's NS5A inhibitors. EDP-239 is a direct-acting anti-viral (DAA) that directly inhibits replication of HCV. Alisporivir (DEB025) blocks HCV replication by targeting proteins in the host cell that are critical to replication of the hepatitis C virus (HCV). As a host-targeting antiviral (HTA), alisporivir (DEB025) is expected to have a high barrier to HCV resistance. It has also demonstrated in vitro anti-HCV activity across multiple HCV genotypes. As the most advanced oral HTA, alisporivir (DEB025), when combined with EDP-239, may be an attractive drug combination for the next-generation of interferon-free HCV therapies. The phase 1 combination study conducted by Novartis is investigating the pharmacokinetics, safety, and tolerability of alisporivir (DEB025) and EDP-239 when co-administered to healthy adult subjects and is scheduled to enroll 42 healthy subjects.
Enanta Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 02:00 PM
Jul 24 14
Enanta Pharmaceuticals, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 02:00 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Jay R. Luly, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|